Telix provides updates on precision medicine pipeline
December 22, 2025 | 11:16
The company reported progress on a key China trial and US regulatory resubmissions for two diagnostic imaging agents.
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
October 23, 2025 | 16:17
Telix Pharmaceuticals Limited today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090.
IMRA Telix Partnership 2025: Radio Guided Surgery Training Push
September 23, 2025 | 15:47
Joint courses will train five hundred surgeons across Asia Pacific, handing medical educators radio surgery keywords and syllabus link.
Telix doubles revenue, fuels pipeline sprint
August 21, 2025 | 21:44
After a 102 % H1 jump, the radiopharma darling bets big on rare cancers—will cash burn outrun the clock?
Telix to Host Webcast on H1 2025 Financial Results
July 30, 2025 | 10:00
Investors tune in as Telix unpacks progress and plans for its precision medicine pipeline.
Telix Showcases Innovation at ANZSNM 2025 Scientific Meeting
May 20, 2025 | 08:00
The nuclear medicine pioneer highlights cutting-edge diagnostic and therapeutic solutions in Sydney.
Telix Gains French Approval for Illuccix PSMA-PET Imaging Agent
April 29, 2025 | 15:35
The green light paves the way for wider access to advanced prostate cancer diagnostics across Europe.
IPAX-Linz Study Shows Promise for TLX101 Glioma Therapy Candidate
April 16, 2025 | 14:29
Telix Pharmaceuticals Limited, today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma.
Telix Appoints Paul Schaffer as Chief Technology Officer
April 07, 2025 | 14:10
Telix Pharmaceuticals Limited today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Telix Doses First Patient in Pioneering ZOLAR Trial for Advanced Soft Tissue Sarcoma
April 02, 2025 | 11:05
Telix Pharmaceuticals Limited today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia.
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
March 04, 2025 | 04:58
Telix Pharmaceuticals Limited invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology.
Illuccix® Receives European Approval
January 17, 2025 | 05:14
Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization Application for its prostate cancer PET imaging agent Illuccix®, which was submitted in Europe via a decentralized procedure (DCP).
FDA accepts new drug application and grants priority review for TLX101-CDx brain cancer imaging agent
October 24, 2024 | 05:02
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has accepted the new drug application for TLX101-CDx.
Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 18, 2024 | 04:32
Telix Pharmaceuticals Limited announces that it has publicly filed a Form 20-F registration statement with the United States Securities and Exchange Commission relating to a proposed listing of American Depository Shares, representing the Company's ordinary shares, on the Nasdaq Stock Market.
Mobile Version